Cardiovascular Effects of Linagliptin

In a randomized trial, this diabetes drug conferred neither CV benefits nor CV harms.

New diabetes medications must demonstrate cardiovascular (CV) safety. In this manufacturer-sponsored, randomized trial, researchers examined the CV safety of linagliptin (Tradjenta), a dipeptidyl peptidase-4 (DPP-4) inhibitor, in nearly 7000 patients with type 2 diabetes and high CV and renal risk. Enrollment criteria included glycosylated hemoglobin (HbA_1c) of 6.5% to 10%; history of coronary, cerebrovascular, or peripheral vascular disease; and reduced glomerular filtration rate (GFR) or albuminuria.

Patients received linagliptin (5 mg daily) or placebo for an average of 2.2 years. The primary outcome (myocardial infarction, stroke, or CV-related death) occurred in 12% of both groups. Adverse renal outcomes (defined largely by >40% decline…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Cardiovascular Effects of Linagliptin

Topics

Reviewing Author